期刊
BRITISH JOURNAL OF DERMATOLOGY
卷 172, 期 1, 页码 169-174出版社
WILEY
DOI: 10.1111/bjd.13167
关键词
-
类别
资金
- NIAMS NIH HHS [R21 AR066286, K24-AR 02207, K24 AR002207] Funding Source: Medline
BackgroundCutaneous dermatomyositis (DM) disease activity is associated with decreased quality of life. ObjectivesTo assess if an improvement in quality of life, as measured by the Skindex-29 and patient-reported itch and pain on a 10-point visual analogue scale (VAS), correlated with an improvement in cutaneous DM disease activity. MethodsPatients with a completed cutaneous DM disease area and severity index [Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI)] at two visits separated by at least 2months were classified into responder (n=15) and nonresponder (n=30) groups according to the point change in the CDASI activity scores between visits. Responders had at least a four-point improvement in CDASI activity, indicating clinically relevant improvement. ResultsThe change from baseline to the follow-up visit of the Skindex-29 subscale scores for the responders vs. the nonresponders were significantly different for emotions (P<001), functioning (P<001) and symptoms (P<001). The change in VAS score between responders and nonresponders was also significant for itch (P=001) and pain (P=004). There was no significant difference between the groups in terms of disease subtype, sex, race, age, treatment for DM, smoking history or a history of malignancy within 5years of a diagnosis of DM. ConclusionsThis is the first study to demonstrate that the quality of life of patients with DM improved as their cutaneous disease activity decreased.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据